SP Accure Labs Private Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: SP Accure Labs Private Limited Pharmaceutical Export Portfolio Dataset — 14 Products, $3.5M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

SP Accure Labs Private Limited — Pharmaceutical Exporter Profile (2026) | 14 Products, $3.5M Trade | TransData Nexus

SP Accure Labs Private Limited

Indian Pharmaceutical Exporter · Oncology Specialist · $3.5M Total Trade · DGFT Verified

SP Accure Labs Private Limited is an Indian pharmaceutical exporter with a total trade value of $3.5M across 14 products in 3 therapeutic categories. Based on 248 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Paclitaxel ($1.3M), Protein ($362.4K), Bortezomib ($315.0K).

SP Accure Labs Private Limited — Export Portfolio & Destination Treemap

SP Accure Labs Private Limited pharmaceutical export portfolio — 14 products across 3 therapeutic categories. Source: Indian Customs (DGFT).

Who is SP Accure Labs Private Limited? — Company Overview & Market Position

SP Accure Labs Private Limited, established on September 30, 2013, is a private pharmaceutical company headquartered in Hyderabad, Telangana, India. The company is registered under the Corporate Identification Number (CIN) U24232TG2013PTC090271. As of the latest available data, SP Accure Labs has an authorized capital of ₹18.00 crore and a paid-up capital of ₹17.64 crore. The company is unlisted and operates in the manufacturing sector, focusing on pharmaceutical products.

The company's registered office is located at 18-17/1/F-2, City Home Residency, Road No 3 Kamala Nagar, Hyderabad, Telangana, 500060, India. SP Accure Labs specializes in the innovation and manufacturing of high-quality oncology and anticancer drugs, offering a comprehensive portfolio of oral and injectable cancer medications.

What Does SP Accure Labs Private Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Paclitaxel$1.3M 2Protein

Product Portfolio — Top 14 by Export Value

SP Accure Labs Private Limited exports 14 pharmaceutical products across 3 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Paclitaxel	Oncology	$1.3M	66	1.5%	13
2	Protein	Nutritional Supplements	$362.4K	19	2.4%	7
3	Bortezomib	Advanced Oncology	$315.0K	24	1.4%	9
4	Pazopanib	Advanced Oncology	$300.0K	6	3.6%	2
5	Cyclophosphamide	Oncology	$272.7K	22	1.4%	5
6	Cisplatin	Oncology	$233.8K	27	1.8%	10
7	Carmustine	Advanced Oncology	$229.6K	23	1.0%	5
8	Melphalan	Advanced Oncology	$155.0K	30	1.2%	6
9	Lenalidomide	Advanced Oncology	$149.5K	7	0.0%	9
10	Vinblastine	Oncology	$98.2K	11	13.1%	2
11	Busulfan	Advanced Oncology	$52.3K	4	1.1%	6
12	Olaparib	Advanced Oncology	$40.4K	3	4.4%	5
13	Mitoxantrone	Advanced Oncology	$27.3K	3	1.4%	4
14	Chlorambucil	Advanced Oncology	$16.0K	3	4.7%	3

SP Accure Labs Private Limited exports 14 pharmaceutical products across 3 therapeutic categories with a total export value of $3.5M. The top category is Oncology (53.0% of portfolio), followed by Advanced Oncology (36.7%), indicating a concentrated portfolio with the top 5 products accounting for 71.4% of total export value.

SP Accure Labs Private Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

SP Accure Labs operates state-of-the-art manufacturing facilities in Hyderabad, Telangana, India. These facilities are designed to produce a wide range of oncology formulations, including both oral solid dosage forms and injectable products. The company emphasizes compliance with international quality standards, ensuring the production of high-quality pharmaceutical products.

3Key Leadership

The leadership team at SP Accure Labs includes:

Vijayaprakash Katikala: Director

Manikya Swarna Latha Kodali: Director

These individuals have been instrumental in steering the company's strategic direction and growth.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does SP Accure Labs Private Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

SP Accure Labs has established a significant presence in several regulated markets, including the United Kingdom, Europe, Canada, and South Korea. The company has obtained certifications from global regulatory bodies such as the European Medicines Agency (EMA), Canada Health GMP, and Malaysia GMP, validating its commitment to quality and safety.

2Emerging Markets

SP Accure Labs actively participates in international tenders with organizations like UNGM, UNOPS, and UNICEF, contributing to advancements in cancer treatment. This engagement facilitates access to emerging markets, particularly in Africa, Latin America, and Southeast Asia. The company's adherence to international quality standards, as evidenced by its certifications, enhances its ability to penetrate these markets.

3Geographic Strategy

SP Accure Labs demonstrates a diversified geographic strategy by establishing a strong foothold in both regulated and emerging markets. This approach mitigates concentration risk and positions the company for sustainable growth across various regions. The strategic direction focuses on expanding market access while maintaining high-quality standards.

SP Accure Labs Private Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

As of the latest available data, specific details regarding SP Accure Labs' FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not publicly disclosed. The company has not been subject to any FDA Form 483 observations, warning letters, or import alerts. This suggests a favorable compliance record with the FDA.

2WHO & EU GMP

SP Accure Labs holds certifications from the European Medicines Agency (EMA), Canada Health GMP, and Malaysia GMP, indicating compliance with international Good Manufacturing Practices (GMP) standards. These certifications validate the company's commitment to producing high-quality pharmaceutical products.

3CDSCO & Indian Regulatory

SP Accure Labs operates under the regulatory framework of the Central Drugs Standard Control Organisation (CDSCO) in India. The company holds manufacturing licenses and approvals from state drug controllers, ensuring compliance with Indian pharmaceutical regulations. Specific details regarding export No Objection Certificates (NOCs) are not publicly disclosed.

SP Accure Labs Private Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

SP Accure Labs operates in the competitive oncology pharmaceutical sector, facing competition from both domestic and international companies. While specific competitors are not identified in the available data, the company's focus on high-quality oncology formulations and adherence to international standards position it favorably in the market.

2Key Differentiators

SP Accure Labs' key differentiators include its specialization in oncology generics, offering an extensive portfolio of oral and injectable cancer medications. The company's commitment to quality is validated by certifications from global regulatory bodies such as the EMA, Canada Health GMP, and Malaysia GMP. Additionally, SP Accure Labs actively participates in international tenders with organizations like UNGM, UNOPS, and UNICEF, contributing to advancements in cancer treatment.

3Strategic Position

SP Accure Labs is strategically positioned as a manufacturer of oncology generics, focusing on both oral and injectable formulations. The company's adherence to international quality standards and active participation in global tenders underscore its commitment to expanding its market presence. The future outlook appears positive, with opportunities for growth in both regulated and emerging markets.

Buyer Due Diligence Brief — Evaluating SP Accure Labs Private Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

SP Accure Labs has demonstrated a consistent track record in manufacturing high-quality oncology formulations. The company's export volume and consistency are supported by certifications from global regulatory bodies, indicating reliability in meeting international standards. While specific export volumes are not detailed, the company's active participation in international tenders suggests a robust export performance.

2Certifications to Verify

Importers should verify the following certifications to ensure product quality and compliance:

FDA Approval: Confirm the FDA approval status of specific products by checking the FDA's Orange Book or contacting the FDA directly.

WHO-GMP: Verify WHO-GMP certification through the World Health Organization's official website or by contacting the organization.

EU GMP: Check for EU GMP certification by consulting the European Medicines Agency's official website or contacting the agency.

Frequently Asked Questions — SP Accure Labs Private Limited

How many pharmaceutical products does SP Accure Labs Private Limited export from India?

SP Accure Labs Private Limited exports 14 pharmaceutical products across 3 therapeutic categories. The top exports are Paclitaxel ($1.3M), Protein ($362.4K), Bortezomib ($315.0K), Pazopanib ($300.0K), Cyclophosphamide ($272.7K). Total export value is $3.5M.

What is SP Accure Labs Private Limited's total pharmaceutical export value?

SP Accure Labs Private Limited's total pharmaceutical export value is $3.5M, based on 248 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does SP Accure Labs Private Limited cover?

SP Accure Labs Private Limited exports across 3 therapeutic categories. The largest are Oncology (53.0%, 4 products), Advanced Oncology (36.7%, 9 products), Nutritional Supplements (10.3%, 1 products).

Get Full SP Accure Labs Private Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.